share_log

In8bio | 424B5: Prospectus

SEC announcement ·  May 7 16:14
Summary by Moomoo AI
In8bio has filed a prospectus supplement with the Securities and Exchange Commission, amending its previous prospectus dated November 21, 2022. The supplement, dated May 7, 2024, allows for the offer and sale of up to $8,900,000 of In8bio's common stock under a Controlled Equity Offering with Cantor Fitzgerald & Co. as the Sales Agent. To date, In8bio has sold 8,392,204 shares for gross proceeds of approximately $15.9 million. The company is limited by General Instruction I.B.6 of Form S-3 in the amount it can sell, which currently stands at an aggregate offering price of up to $8,900,000, considering the current public float. In8bio's common stock is traded on the Nasdaq Global Market under the symbol 'INAB'. The market value of non-affiliate held common stock was $41.5 million as of May...Show More
In8bio has filed a prospectus supplement with the Securities and Exchange Commission, amending its previous prospectus dated November 21, 2022. The supplement, dated May 7, 2024, allows for the offer and sale of up to $8,900,000 of In8bio's common stock under a Controlled Equity Offering with Cantor Fitzgerald & Co. as the Sales Agent. To date, In8bio has sold 8,392,204 shares for gross proceeds of approximately $15.9 million. The company is limited by General Instruction I.B.6 of Form S-3 in the amount it can sell, which currently stands at an aggregate offering price of up to $8,900,000, considering the current public float. In8bio's common stock is traded on the Nasdaq Global Market under the symbol 'INAB'. The market value of non-affiliate held common stock was $41.5 million as of May 7, 2024, based on a closing price of $1.30 per share on March 8, 2024. In the past 12 months, In8bio has sold $4,926,024 worth of securities under the same instruction. The company cautions that investing in its securities involves high risk, advising investors to review the 'Risk Factors' section in the Prior Prospectus and its most recent financial reports.

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more